Alligator Bioscience’s Rights Offering

Baker McKenzie advised the Joint Bookrunners on the deal. Setterwalls has advised Alligator Bioscience AB.

Alligator Bioscience has completed an oversubscribed preferential rights issue of approximately SEK 257 million (approx. $28.5 million).

Alligator Bioscience is a biotechnology company in the clinical phase that develops antibody-based pharmaceuticals for cancer treatment.

DNB Markets and Redeye acted as Joint Bookrunners in the transaction.

The Baker McKenzie consisted of Joakim Falkner (Picture), Johanna Flink and Nanna Trulsson.

The Setterwalls team included Ola Grahn, Ludwig Isell Lind af Hageby, Joakim Winnerljung, Erik Olshov.

Involved fees earner: Joakim Falkner – Baker McKenzie; Johanna Flink – Baker McKenzie; Nanna Trulsson – Baker McKenzie; Ludwig Isell Lind af Hageby – Setterwalls; Ola Grahn – Setterwalls; Erik Olshov – Setterwalls; Joakim Winnerljung – Setterwalls;

Law Firms: Baker McKenzie; Setterwalls;

Clients: Alligator Bioscience AB; DNB Markets; Redeye;